TargetBeta
CHRM4
cholinergic receptor muscarinic 4 · Cholinergic receptors muscarinic
6 programs in company-led studies act on CHRM4, from 3 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 3825 running | CHRM1 | ChEMBL |
| Glycopyrrolaterule | Novartis | phase 4 | 873 running | CHRM1, CHRM2, CHRM3, CHRM5 | ChEMBL |
| emraclidine | AbbVie | phase 2 | 182 running | – | the company's pipeline |
| GXV-813 | Novartis | phase 2 | 11 running | – | the company's pipeline |
| BMS-986521 | Bristol-Myers Squibb | phase 1 | 11 running | – | a judged reading |
| ABBV-1042 | AbbVie | phase 1 | 10 running | – | the company's pipeline |
Conditions their studies are in
- Schizophrenia, 3 programs
- Alzheimer Disease, 2 programs
- Renal Insufficiency, 2 programs
- Asthma, 1 program
- Autism Spectrum Disorder, 1 program
- Hyperhidrosis, 1 program
- Mania, 1 program
- Nausea, 1 program
- Pulmonary Disease, Chronic Obstructive, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 24, 2026xanomeline · Bristol-Myers Squibb · phase 4 · NCT06585787
- Dec 2026emraclidine · AbbVie · phase 2 · NCT07219030
- Dec 27, 2026BMS-986521 · Bristol-Myers Squibb · phase 1 · NCT07655518
- May 31, 2027Glycopyrrolate · Novartis · phase 4 · NCT07073950
- Jul 29, 2027GXV-813 · Novartis · phase 2 · NCT07467993
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.